Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes

被引:54
作者
Holguín, A
Paxinos, E
Hertogs, K
Womac, C
Soriano, V
机构
[1] Hosp Carlos III, Infect Dis Serv, Madrid, Spain
[2] ViroLogic, San Francisco, CA USA
[3] Virco, Mechelen, Belgium
[4] NIH, Bethesda, MD 20892 USA
关键词
HIV-1; non-B subtypes; drug resistance; protease inhibitors; natural polymorphisms;
D O I
10.1016/j.jcv.2004.03.015
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Naturally-occurring polymorphisms at the human immunodeficiency virus type 1 (HIV- 1) protease which have been associated to resistance to protease inhibitors (PIs) in clade B viruses are frequently found in non-B subtypes, with unknown clinical significance, Objective: To assess the susceptibility of non-B viruses to different PIs. Study design: Plasma samples from 58 drug-naive individuals infected with HIV-1 non-B subtypes (2A, 22C, 2D, 1F, 29G and 2J) defined by phylogenetic analyses of the protease gene were tested using a phenotypic assay (PhenoSense, ViroLogic, South San Francisco, CA, USA). Twenty of them were further analyzed with another assay (Antivirogra(TM), Virco, Mechelen, Belgium). All 58 non-B viruses harbored amino acid substitutions associated with reduced PI susceptibility in clade B (positions 10, 20 36, 63 70, 77 and 82). Results: Using PhenoSense-HIV(TM) assay, all but two individuals harbored viruses completely susceptible to all six PIs tested (indinavir (IDV), ritonavir (RTV), saquinavir (SQV), nelfinavir (NFV), amprenavir (APV), lopinavir (LPV)). The two viruses with reduced susceptibility belonged to clade G. The first virus, which had K20I, M36I and V82I, showed 2.9-fold decreased susceptibility to APV. while the second virus showed 3.9-fold decreased susceptibility to both NFV and RTV, with amino acid substitutions K20I, M36I, L63P an V82I. Of note, several other viruses displayed the same constellation of mutations but without showing any reduced susceptibility, suggesting that these polymorphisms per se do not affect PI susceptibility. Conclusion: PI susceptibility in HIV-1 non-B viruses seems to be preserved despite the presence of polymorphic changes which have been associated to PI resistance in clade B viruses. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:215 / 220
页数:6
相关论文
共 59 条
[31]   Recombinant human immunodeficiency viruses type 1 circulating in Spain [J].
Holguín, A ;
Rodés, B ;
Soriano, V .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2000, 16 (05) :505-511
[32]   HIV-1 subtype J recombinant viruses in Spain [J].
Holguín, A ;
Alvarez, A ;
Soriano, V .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2002, 18 (07) :523-529
[33]   High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid [J].
Holguín, A ;
Alvarez, A ;
Soriano, V .
AIDS, 2002, 16 (08) :1163-1170
[34]   Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5 [J].
Holguín, A ;
Aracil, B ;
Alvarez, A ;
Barros, C ;
Soriano, V .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (05) :1850-1854
[35]  
Holguin Africa, 2002, HIV Clin Trials, V3, P403
[36]  
ISAACSON I, 2002, P 9 C RETR OPP INF S
[37]   Erroneously low or undetectable plasma human immunodeficiency virus type 1 (HIV-1) ribonucleic acid load determined by polymerase chain reaction, in West African and American patients with non-B subtype HIV-1 infection [J].
Jenny-Avital, ER ;
Beatrice, ST .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (08) :1227-1230
[38]  
KUIKEN C, 2000, HIV SEQUENCE COMPEDI
[39]   Genetic divergence of human immunodeficiency virus type I Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT [J].
Loemba, H ;
Brenner, B ;
Parniak, MA ;
Ma'ayan, S ;
Spira, B ;
Moisi, D ;
Oliveira, M ;
Detorio, M ;
Wainberg, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) :2087-2094
[40]   Impact of drug resistance mutations on virologic response to salvage therapy [J].
Lorenzi, P ;
Opravil, M ;
Hirschel, B ;
Chave, JP ;
Furrer, HJ ;
Sax, H ;
Perneger, TV ;
Perrin, L ;
Kaiser, L ;
Yerly, S .
AIDS, 1999, 13 (02) :F17-F21